Call for Abstracts
Abstract Submission Period
Abstracts for oral, poster
Tuesday, 16th, July – Monday, 2nd, September 2024
Presentation Categories
Please select the most appropriate category for your presentation.
Presentation style
Oral presentation
Symposium
Digital Innovation in Gastric Cancer Science: Advances in Navigation Surgery
Digital Innovation in Gastric Cancer Science: Advances in Endoscopic and Pathological Diagnosis of Gastric Cancer
Digital Innovation in Gastric Cancer Science: Advances in Education for Young Physicians and Surgeons
Video Symposium
Digital Innovation in Gastric Cancer Science: Evolution of Robotic Gastrectomy
Digital Innovation in Gastric Cancer Science: Evolution of Endoscopic Treatment Techniques for Early Gastric Cancer
Panel Discussion
Optimal Surgery for UM Junction Gastric Cancer: Proximal Gastrectomy vs. Distal Gastrectomy
Optimal Treatment for Early Gastric Cancer in the Elderly: ESD vs. Reduced Surgery (Sentinel) vs. Standard Surgery
What is the Optimal Conversion Surgery?
Cross-disciplinary Treatment: Optimal Treatment for Esophagogastric Junction Cancer from the Perspectives of Gastroenterologists, Esophageal Surgeons, Gastric Surgeons, and Medical Oncologists
Video Panel Discussion
Optimal Surgery for Gastric Cancer Invading the Greater Curvature: Splenectomy vs. Splenic Hilum Lymph Node Dissection
Workshop
Clinical Research in Gastric Cancer in the Digital Innovation Era
Molecular Biology and Genetics of Gastric Cancer in the Digital Innovation Era
Gastric Cancer Management in the Digital Innovation Era: H. pylori-negative Gastric Cancer
"Best Practices in Perioperative Management for Elderly Patients in the Digital Innovation Era
Multidisciplinary Treatment for Gastric GIST in the Digital Innovation Era
Innovations in Minimally Invasive Gastric Cancer Surgery in the Digital Innovation Era
Innovations in LECS/D-LECS Techniques in the Digital Innovation Era
Latest Treatments for Scirrhous Gastric Cancer
Addressing irAE: Diagnosis, Treatment, and Countermeasures
Cutting edge of endoscopic management for adverse events related to gastric ESD/surgery (bleeding, perforation and anastomotic leakage), including wound closure and stent placement
Mini Oral / Poster Session Categories
1 | Epidemiology |
---|---|
2 | Molecular biology |
3 | Pathology |
4 | Genomics |
5 | Translational research |
6 | Biomarker |
7 | Tumor microenvironment |
8 | AI |
9 | Endoscopic therapy |
10 | Endoscopic diagnosis |
11 | Imaging diagnosis |
12 | H.pylori |
13 | Progression of gastric cancer |
14 | Rare metastasis / Micrometastasis |
15 | Intraoperative frozen section |
16 | Cancer stem cell |
17 | Clinical pathology |
18 | Prognostic factor |
19 | Precision medicine |
20 | Clinical study |
21 | Chemotherapy |
22 | Neoadjuvant chemotherapy |
23 | Adjuvant chemotherapy |
24 | Second-line chemotherapy |
25 | Third-line chemotherapy |
26 | Intraperitoneal chemotherapy |
27 | Molecular targeted therapy |
28 | Immunotherapy |
29 | Radiation therapy |
30 | conversion surgery |
31 | Surgery |
32 | Laparoscopic surgery |
33 | Robot surgery |
34 | Function-preserving surgery |
35 | Cytoreductive surgery |
36 | LECS |
37 | Surgical navigation |
38 | Postoperative functional assessment |
39 | Postgastrectomy syndrome |
40 | Perioperative management |
41 | Postoperative complications |
42 | ERAS |
---|---|
43 | Navigation Surgery |
44 | Peritoneal dissemination |
45 | CART |
46 | Stent placement |
47 | Liver metastasis |
48 | Recurrence |
49 | Early gastric cancer |
50 | Advanced gastric cancer |
51 | Scirrhous gastric cancer |
52 | Gastric stump carcinoma |
53 | Multiple gastric cancers |
54 | Gastric tube cancer |
55 | Esophago-gastric junction cancer |
56 | Gastric cancer in elderly patients |
57 | AFP-producing gastric cancer |
58 | EBV-related gastric cancer |
59 | Gastrointestinal stromal tumor |
60 | Malignant lymphoma |
61 | Gastric neuroendocrine tumor |
62 | Guidelines |
63 | Clinical pathway |
64 | Postoperative surveillance |
65 | Long-term survival case after chemotherapy |
66 | NST |
67 | Outcome |
68 | QOL assessment |
69 | Cachexia |
70 | Nutrition |
71 | Obesity |
72 | Case report |
73 | Japanese Classification of Gastric Carcinoma |
74 | Multidisciplinary treatment |
75 | Palliative therapy |
76 | Team approach |
77 | Patient Advocacy |
78 | MDT conference |
79 | Medical cooperation |
80 | Oral care |
81 | EFTR |
82 | Others |
Abstract Acceptance or Rejection
Please note that the decision on abstract acceptance/rejection is left to the sole discretion of the Congress President.
Abstract Submission
Language for abstract
English
Language for presentation
English
Language for presentation slides
English
The number of characters
Title: up to 100 characters (including spaces)
Abstract: up to 1600 characters (including spaces)
Conflict of Interest Disclosure
The author is required to report applicable COI (Conflict of Interest) by completing the “Conflict of Interest Disclosure” part in the Abstract Submission process.
Abstract Submission
Inquiries
Secretariat of 97th Annual Meeting of The Japanese Gastric Cancer Association
c/o Japan Convention Services, Inc.
14F Daido Seimei Kasumigaseki Bldg.
1-4-2, Kasumigaseki, Chiyoda-ku,
Tokyo 100-0013, Japan
E-mail: endai-97jgca@convention.co.jp